Stuart Gallagher

University of Sydney — Australia

Medicine · Health Sciences

29h-index4.1kcitations87works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(17), Epigenetics and DNA Methylation(16), Histone Deacetylase Inhibitors Research(16), Melanoma and MAPK Pathways(13), Protein Degradation and Inhibitors(12)

Publications81 total

Commercial Impacts on Assisted Reproductive Technology: A Scoping Review
Journal of Bioethical Inquiry·2025Open Access
Increased neuronal activity restores circadian function in <i>Drosophila</i> models of C9orf72-ALS/FTD
2025Open Access
Youth Designers’ Insights on Information Literacy Learning Tools
Proceedings.·2025Open Access
Why don't they teach education at school?
2025
Assessment and feedback
2025
Safeguarding: understanding your responsibilities
2025
Contributors
Elsevier eBooks·2025Open Access
233VP Review of inpatient care of children affected by neuromuscular disorders or complex neurodisability from the carer perspective
Neuromuscular Disorders·2024
<scp>BET</scp> inhibition sensitizes innate checkpoint inhibitor resistant melanoma to <scp>anti‐CTLA</scp>‐4 treatment
Pigment Cell & Melanoma Research·2024· 4 citedOpen Access
Creating hope in dystopia: Utopia as Method as social pedagogy in early childhood studies
International Journal of Social Pedagogy·2023· 4 citedOpen Access
Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma
Journal of Investigative Dermatology·2021· 17 cited
Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma
2021· 2 citedOpen Access
Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis
Pathology·2021· 12 cited
A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
Journal of Investigative Dermatology·2021· 12 cited
Sex bias of females in survival from cancer and infections. Is X the answer?
British Journal of Cancer·2021· 10 citedOpen Access
Abstract LB-177: BET and CDK9 protein inhibitors: Novel epigenetic therapy to synergistically kill human melanoma cells
Cancer Research·2020
Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts
Cancers·2020· 19 citedOpen Access
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
Journal of Investigative Dermatology·2020· 60 cited
Co‐targeting bromodomain and extra‐terminal proteins and <scp>MCL1</scp> induces synergistic cell death in melanoma
International Journal of Cancer·2020· 21 citedOpen Access
Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition
International Journal of Oncology·2020· 29 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Peter Hersey(32), Jessamy Tiffen(24), Dilini Gunatilake(12), Helen Rizos(11), Abdullah Al Emran(11), Kavitha Gowrishankar(7), Lionel Larue(7), Hsin‐Yi Tseng(7), Carleen Cullinane(6), Michael R. Eccles(5), Grant A. McArthur(5), Fabian V. Filipp(5), Véronique Delmas(4), Elena Shklovskaya(4), James S. Wilmott(4), Branka Mijatov(4), Richard Kefford(4), Mark A. Creager(3), Aniruddha Chatterjee(3), Euan J. Rodger(3)